SCHEMBL6201177

SCHEMBL6201177

CC(=O)n1cnc(C(N)=O)n1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ADORA1 P30542 2/20 0.38
ALDH1A1 P00352 2/20 0.38
GLA P06280 1/20 0.38
EIF4E P06730 1/20 0.38
CYP3A4 P08684 1/20 0.38
TOP1 P11387 1/20 0.38
TSHR P16473 1/20 0.38
THPO P40225 1/20 0.38
PMP22 Q01453 1/20 0.38
HTR2C P28335 1/20 0.36
HTR2B P41595 1/20 0.36
SLC6A3 Q01959 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
KMT2A Q03164 2/20 0.32
MEN1 O00255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11743344 0.77 LMNA (0.37) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL65249 0.75
SCHEMBL28241233 0.72 LMNA (0.41) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL11748198 0.71 ELANE (0.38) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12921936 0.71 LMNA (0.43) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL784347 0.71 ADORA1 (0.40) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL13757852 0.71 LMNA (0.40) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL11746122 0.70 KDM4E (0.49) SMN1; SMN2ALDH1A1TSHRKMT2AMEN1
SCHEMBL6198132 0.69 LMNA (0.36) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL24239204 0.68 LMNA (0.35) LMNASMN1; SMN2ADORA1ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239835-A1 Melanocortin receptor ligands EBETINO FRANK H 2005-10-27 US disclosed
EP-1499314-A1 N-ACYL PIPERIDINE DERIVATIVES FOR USE AS MELANOCORTIN RECEPTOR LIGANDS IN THE TREATMENT OF FEEDING DISORDERS The Procter & Gamble Company (US) 2005-01-26 EP disclosed
US-20040010010-A1 Melanocortin receptor ligands PROCTER & GAMBLE COMPANY, THE 2004-01-15 US disclosed
WO-2003092690-A1 N-ACYL PIPERIDINE DERIVATIVES FOR USE AS MELANOCORTIN RECEPTOR LIGANDS IN THE TREATMENT OF FEEDING DISORDERS THE PROCTER & GAMBLE COMPANY (US) 2003-11-13 WO disclosed
US-4006159-A ACYL, VIRICIDES AMERICAN CYANAMID COMPANY (US) 1977-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239835-A1 Melanocortin receptor ligands MC1R, MC4R, MC3R LMNA 4226/4885SMN1; SMN2 3611/4885ADORA1 501/4885
US-20040010010-A1 Melanocortin receptor ligands MC1R, MC4R, MC5R LMNA 4253/4885SMN1; SMN2 3695/4885ADORA1 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.